spacer
home > ebr > spring 2002 > interim management within life science companies
PUBLICATIONS
European Biopharmaceutical Review

Interim Management Within Life Science Companies

Reaching what are often well publicised milestones, or striving to gain or retain a competitive advantage is very much about taking calculated risks, about making decisions where the outcome is less than certain. If there is a successful outcome, the hero is born - if only for a day. If companies do stumble somewhat, then let us applaud the fact that there was courage enough for a decision in the first place. Then let us learn and move forward.

But What if Progress is Hindered Due to Avoidable Causes?

It is people who make decisions, and who subsequently implement them, and in today's tough and unforgiving marketplace, the absence of experienced and competent individuals within an organisation is now rightly deemed to be unacceptable. Indeed, the permanent recruitment of high quality staff is critical and does take time, but not having the right people in the right place - exactly when they are needed - is simply not acceptable anymore.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Geoff Newman, Managing Director of Interea International Ltd

Geoff Newman is the Co-Founder and Managing Director of Interea International, a provider of senior level Interim Management to the UK and international life sciences sector. Geoff graduated with First Class Honours in Chemistry from Durham University, before joining the pharmaceutical industry.
His career has encompassed commercial and general management roles within a number of companies, and has included significant overseas postings in Switzerland, Japan and the US.

spacer
Geoff Newman
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Nemera announces a better drug deposition with RetroNose to enhance therapeutic efficacy of nasal treatments

After announcing a partnership with the Research Center for Respiratory Diseases (CEPR) of Inserm/University of Tours in April 2017, Nemera is happy to publish enhanced drug deposition results compared to classic nasal sprays with RetroNose.
More info >>

White Papers

Device Develop for Combo Products

Phillips-Medisize

Combination products are defined as therapeutics combining two or more products (drug/device, biologics/device, biologics/drugs or drug/device/biologics), regulated and sold as a single unit. As these pharmaceutical and biological therapies and treatments have evolved, so has the need to develop appropriate delivery mechanisms for these applications. When developing a combination product, there are many things that need to be considered – the critical relationships between device development and the pharmaceutical or biologic, early establishment of regulatory and clinical strategies, understanding ‘user’ needs, determining product requirements, as well as, device manufacturing variation.
More info >>

 
Industry Events

SAPHEX 2019

23-24 October 2019, GALLAGHER CONVENTION CENTRE, 10 RICHARDS DRIVE, HALFWAY HOUSE, MIDRAND, 1685, SOUTH AFRICA

SAPHEX 2019 will be held on the 23rd-24th October at the Gallagher Convention Centre, Johannesburg, South Africa.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement